Medical management of primary pulmonary hypertension

Primary pulmonary hypertension (PPH) is a poorly understood, progressive disease that is characterized by elevation of pulmonary artery pressure and vascular resistance, leading to right ventricular failure and death within 2-3 yrs after diagnosis. Based upon the concept that vasoconstriction and thrombotic occlusion of resistance vessels precipitate this process, vasodilator therapy and anticoagulation have become the main strategies for improving survival in these patients. Whereas, a few years ago, medical therapy of primary pulmonary hypertension was perceived as a bridging therapy to lung or heart lung transplantation, modes of therapy are being clinically tested at this time to offer an alternative to the surgical treatment of this disease. However, no selective pulmonary vasodilator is yet available. Therefore, and because of the potential hazards of vasodilator treatment, standardized haemodynamic testing is performed prior to initiation of vasodilator treatment. In this update, the currently available compounds both for haemodynamic testing and chronic therapy, their mode of action, method of administration and efficacy are reviewed.

This article has been cited by other articles:

				A.T. Dinh-Xuan, M. Humbert, and R. Naeije Severe pulmonary hypertension: walking through new paths to revisit an old field Eur. Respir. J., September 1, 2002; 20(3): 509 - 510. [Full Text] [PDF]

				R. Schulz, G. Baseler, H.A. Ghofrani, F. Grimminger, H. Olschewski, and W. Seeger Nocturnal periodic breathing in primary pulmonary hypertension Eur. Respir. J., April 1, 2002; 19(4): 658 - 663. [Abstract] [Full Text] [PDF]

				V. CASTELAIN, D. CHEMLA, M. HUMBERT, O. SITBON, G. SIMONNEAU, Y. LECARPENTIER, and P. HERVE Pulmonary Artery Pressure-Flow Relations after Prostacyclin in Primary Pulmonary Hypertension Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 338 - 340. [Abstract] [Full Text] [PDF]

				E. Papakonstantinou, G. Karakiulakis, M. Tamm, A. P. Perruchoud, and M. Roth Hypoxia modifies the effect of PDGF on glycosaminoglycan synthesis by primary human lung cells Am J Physiol Lung Cell Mol Physiol, November 1, 2000; 279(5): L825 - L834. [Abstract] [Full Text] [PDF]

				A. Y. Saadjian, F. Paganelli, M. L. Reynaud Gaubert, S. Levy, and R. P. Guieu Adenosine plasma concentration in pulmonary hypertension Cardiovasc Res, July 1, 1999; 43(1): 228 - 236. [Abstract] [Full Text] [PDF]

				M. Tamm, M. Bihl, O. Eickelberg, P. Stulz, A. P. Perruchoud, and M. Roth Hypoxia-Induced Interleukin-6 and Interleukin-8 Production Is Mediated by Platelet-Activating Factor and Platelet-Derived Growth Factor in Primary Human Lung Cells Am. J. Respir. Cell Mol. Biol., October 1, 1998; 19(4): 653 - 661. [Abstract] [Full Text]